The estimated Net Worth of R. Hector Mac Kay Dunn is at least $324 Tysiąc dollars as of 21 May 2024. Mr. Dunn owns over 5,630 units of Aurinia Pharmaceuticals Inc stock worth over $121,425 and over the last 4 years he sold AUPH stock worth over $32,316. In addition, he makes $170,374 as Director at Aurinia Pharmaceuticals Inc.
Sign up
Mr. Dunn AUPH stock SEC Form 4 insiders trading
R has made over 4 trades of the Aurinia Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 5,630 units of AUPH stock worth $32,316 on 21 May 2024.
The largest trade he's ever made was exercising 8,733 units of Aurinia Pharmaceuticals Inc stock on 18 May 2023 worth over $57,026. On average, R trades about 3,977 units every 184 days since 2021. As of 21 May 2024 he still owns at least 18,595 units of Aurinia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Dunn stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
R. Hector MacKay-Dunn biography
R. Hector MacKay-Dunn J.D. serves as Director of the Company. Mr. MacKay-Dunn has over 30 years of practice experience providing legal advice to high growth public and private companies, many of which achieving valuations exceeding CDN$1billion over a broad range of industry sectors including life sciences, health, and technology, advising on corporate domestic and cross-border public and private securities offerings, mergers and acquisitions and international partnering and licensing transactions, and boards of directors and independent board committees on corporate governance matters. Mr. MacKay-Dunn is recognized by Lexpert, as being among the Top 100 Canada/U.S. Cross-Border Corporate Lawyers in Canada, has consistently been named among The Leading 500 Lawyers in Canada, and is recognized among Canada’s leading lawyers in mergers & acquisitions, technology and biotechnology. Mr. MacKay-Dunn received the Queen’s Counsel designation upon recommendation by the Attorney General of British Columbia for exceptional merit and contribution to the legal profession, the “AV Preeminent 5.0 out of 5” legal ability rating from Martindale-Hubbell, and is regularly recognized as a leading lawyer nationally by Chambers Canada within the Life Sciences category. Mr. MacKay-Dunn has served as board member or officer with Aspreva Pharmaceuticals Corporation, Arbutus Biophara Corp., XBiotech Inc., MedGenesis Therapeutix Inc., and QLT Inc., is a board member of the BC (British Columbia) Tech Association, previously board chair of the Innovation Council of British Columbia, and board member of LifeSciences British Columbia and Genome British Columbia.
What is the salary of R Dunn?
As the Director of Aurinia Pharmaceuticals Inc, the total compensation of R Dunn at Aurinia Pharmaceuticals Inc is $170,374. There are 16 executives at Aurinia Pharmaceuticals Inc getting paid more, with Peter Greenleaf having the highest compensation of $1,678,600.
How old is R Dunn?
R Dunn is 68, he's been the Director of Aurinia Pharmaceuticals Inc since 2019. There are 1 older and 13 younger executives at Aurinia Pharmaceuticals Inc. The oldest executive at Aurinia Pharmaceuticals Inc is George Milne, 76, who is the Independent Chairman of the Board.
What's R Dunn's mailing address?
R's mailing address filed with the SEC is #140, 14315 - 118 AVENUE, , EDMONTON, A0, T5L 4S6.
Insiders trading at Aurinia Pharmaceuticals Inc
Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden oraz Michael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.
What does Aurinia Pharmaceuticals Inc do?
aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.
What does Aurinia Pharmaceuticals Inc's logo look like?
Complete history of Mr. Dunn stock trades at Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc executives and stock owners
Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Peter Greenleaf,
President, Chief Executive Officer, Director -
Peter S. Greenleaf M.B.A.,
Pres, CEO & Director -
Maxwell Donley,
Executive Vice President, Internal Operations & Strategy -
Neil Solomons,
Chief Marketing Officer -
Massimiliano Colao,
Chief Commercial Officer -
Robert Huizinga,
Executive Vice President - Corporate Development -
Matthew Maxwell Donley M.B.A.,
Exec. VP of Operations & Strategy -
Joseph M. Miller CPA,
Chief Financial Officer -
Dennis Bourgeault,
Chief Financial Officer -
Michael Martin,
Chief Operating Officer -
Daniel Billen,
Director -
George Milne,
Independent Chairman of the Board -
Michael Hayden,
Independent Director -
Stephen P. Robertson,
Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer -
Joseph Hagan,
Independent Director -
David Jayne,
Independent Director -
R. Hector MacKay-Dunn,
Director -
Jill Leversage,
Independent Director -
Stephen Robertson,
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary -
Timothy Walbert,
Independent Director -
Max Colao,
Chief Commercial Officer -
Tim Hermes,
Vice President of Market Access -
Cara Felish,
Vice President of Commercial Operations -
Chris Hays,
Vice President of Marketing -
Fran Lynch,
Vice President of Sales -
Glenn Schulman,
Senior Vice President - Corporate Communications and Investor Relations -
Michael R. Martin,
Chief Bus. Officer -
Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
Exec. VP of Research -
Scott Michael Habig,
Chief Commercial Officer -
Volker Knappertz,
EVP, Research and Development -
Joseph M Miller,
Chief Financial Officer -
Brinda Balakrishnan,
Director -
Robert T Foster,
Director -
Massimilano Colao,
Chief Commercial Officer -
Jeffrey Allen Bailey,
Director -
Karen L. Smith,
Director